[논문]Co-treatment of birinapant with TRAIL synergistically induces apoptosis by downregulating cFLIP(L) in MDA-MB-453 cell lines

Park, Eun Jung; Kim, Hae Dong; Choi, Eun Kyoung; Hoe, Kwang-Lae; Kim, Dong-Uk

doi:10.1016/j.bbrc.2020.09.031

[해외논문] Co-treatment of birinapant with TRAIL synergistically induces apoptosis by downregulating cFLIP(L) in MDA-MB-453 cell lines 원문보기

Biochemical and biophysical research communications, v.533 no.3, 2020년, pp.289 - 295

Park, Eun Jung (Rare Disease Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB)) , Kim, Hae Dong (Department of New Drug Discovery and Development, Chungnam National University) , Choi, Eun Kyoung (Rare Disease Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB)) , Hoe, Kwang-Lae (Department of New Drug Discovery and Development, Chungnam National University) , Kim, Dong-Uk (Rare Disease Research Center, Korea Research Institute of Bioscience & Biotechnology (KRIBB))

Abstract ▼ AI-Helper

Abstract Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has received much attention owing to its ability to specifically induce cell death in cancer. However, several types of cancer, including some forms of breast cancer, are resistant to TRAIL. Various chemotherapeutic agents, phytochemicals, and TRAIL combination therapies have been proposed to resolve TRAIL resistance. Here, we explored the sensitization effect of birinapant on TRAIL-induced apoptosis in the MDA-MB-453 cell line. Although neither birinapant nor TRAIL showed any cytotoxic effect when used alone, apoptosis was induced when birinapant and TRAIL were used together. Our data suggest that the combination of birinapant and TRAIL induces downregulation of FLICE-like inhibitory protein (cFLIP) (L) protein expression. Interestingly, cFLIP(L) overexpression reversed apoptosis caused by co-treatment with TRAIL. Taken together, our results indicate that a combination of birinapant and TRAIL may be a promising treatment for TRAIL-resistant breast cancer. Highlights Treatment of Birinapant with TRAIL can lead to the apoptosis of TRAIL-resistance breast cancer cell lines. cFLIP(L) is a key mediator of birinapant plus TRAIL-mediated apoptosis in MDA-MB-453 cell lines. In other types of solid cancer, treatment with birinapant plus TRAIL induces apoptosis.

Keyword

참고문헌 (35)

CA Cancer J. Clin. Bray 68 394 2018 10.3322/caac.21492 Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

상세보기
N. Engl. J. Med. Foulkes 359 2143 2008 10.1056/NEJMra0802968 Inherited susceptibility to common cancers

상세보기
J. Natl. Cancer Inst. Peto 91 943 1999 10.1093/jnci/91.11.943 Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer

상세보기
J. Clin. Oncol. Brenton 23 7350 2005 10.1200/JCO.2005.03.3845 Molecular classification and molecular forecasting of breast cancer: ready for clinical application?

상세보기
Canc. Gene Ther. Zhang 12 228 2005 10.1038/sj.cgt.7700792 Mechanisms of resistance to TRAIL-induced apoptosis in cancer

상세보기
Immunity Kischkel 12 611 2000 10.1016/S1074-7613(00)80212-5 Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5

상세보기
Trends Mol. Med. Stuckey 19 685 2013 10.1016/j.molmed.2013.08.007 TRAIL on trial: preclinical advances in cancer therapy

상세보기
Oncogene Grotzer 19 4604 2000 10.1038/sj.onc.1203816 Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression

상세보기
Biochem. Biophys. Res. Commun. Lee 351 1024 2006 10.1016/j.bbrc.2006.10.163 Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation

상세보기
Sm 211 2011 Annual Reports in Medicinal Chemistry The discovery and development of Smac mimetics-small-molecule antagonists of the inhibitor of apoptosis proteins, Chap 13
Breast Canc. Res. Treat. Allensworth 137 359 2013 10.1007/s10549-012-2352-6 Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-alpha-independent mechanism

상세보기
Clin. Canc. Res. Krepler 19 1784 2013 10.1158/1078-0432.CCR-12-2518 The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells

상세보기
J. Med. Chem. Condon 57 3666 2014 10.1021/jm500176w Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies

상세보기
Cell Death Differ. Lalaoui 2020 10.1038/s41418-020-0541-0 Targeting triple-negative breast cancers with the Smac-mimetic birinapant

상세보기
Laryngoscope Eytan 125 E118 2015 10.1002/lary.25056 Combination effects of SMAC mimetic birinapant with TNFalpha, TRAIL, and docetaxel in preclinical models of HNSCC

상세보기
J. Pharmacokinet. Pharmacodyn. Zhu 42 477 2015 10.1007/s10928-015-9429-x Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells

상세보기
Cancer Res. Eytan 76 5442 2016 10.1158/0008-5472.CAN-15-3317 SMAC mimetic birinapant plus radiation eradicates human head and neck cancers with genomic amplifications of cell death genes FADD and BIRC2

상세보기
Oncol. Res. Vetma 25 1489 2017 10.3727/096504017X14897145996933 Examining the in vitro efficacy of the IAP antagonist birinapant as a single agent or in combination with dacarbazine to induce melanoma cell death

상세보기
Cell Death Differ. Crawford 25 1952 2018 10.1038/s41418-018-0082-y Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711

상세보기
J. Pharmacokinet. Pharmacodyn. Zhu 45 733 2018 10.1007/s10928-018-9603-z Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts

상세보기
Cancer Noonan 122 588 2016 10.1002/cncr.29783 Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer

상세보기
Clin. Canc. Res. Srivastava 22 1000 2016 10.1158/1078-0432.CCR-14-3156 Effect of a smac mimetic (TL32711, birinapant) on the apoptotic program and apoptosis biomarkers examined with validated multiplex immunoassays fit for clinical use

상세보기
Mol. Canc. Therapeut. Amaravadi 14 2569 2015 10.1158/1535-7163.MCT-15-0475 A phase I study of the SMAC-mimetic birinapant in adults with refractory solid tumors or lymphoma

상세보기
Cell Death Differ. Porter 6 99 1999 10.1038/sj.cdd.4400476 Emerging roles of caspase-3 in apoptosis

상세보기
Biochim. Biophys. Acta Redza-Dutordoir 1863 2977 2016 10.1016/j.bbamcr.2016.09.012 Activation of apoptosis signalling pathways by reactive oxygen species

상세보기
Clin. Breast Canc. Anders 9 Suppl 2 S73 2009 10.3816/CBC.2009.s.008 Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer

상세보기
Nat. Cell Biol. Muller 15 2 2013 10.1038/ncb2641 p53 mutations in cancer

상세보기
Biochim. Biophys. Acta Fiorini 1853 89 2015 10.1016/j.bbamcr.2014.10.003 Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine

상세보기
Nat. Med. Aas 2 811 1996 10.1038/nm0796-811 Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

상세보기
Breast Cancer Jernstrom 9 185 2017 Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
Cancer Res. Keane 59 734 1999 Chemotherapy augments TRAIL-induced apoptosis in breast cell lines

상세보기
Vitam. Horm. Roth 67 189 2004 10.1016/S0083-6729(04)67011-7 FLIP protein and TRAIL-induced apoptosis

상세보기
Canc. Lett. Shirley 332 141 2013 10.1016/j.canlet.2010.10.009 Targeting c-FLIP in cancer

상세보기
Curr. Cancer Drug Targets Safa 8 37 2008 10.2174/156800908783497087 Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy

상세보기
Cardiovasc. Res. Nitobe 57 119 2003 10.1016/S0008-6363(02)00646-6 Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes

상세보기

LOADING...

활용도 분석정보

상세보기

다운로드

내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증